Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanobody CD5-chimeric antigen receptor T-cells
- Development stage
- Phase 2
- Lead developer
- Senlang Bio
- Modality
- Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
Nanobody CD5-chimeric antigen receptor T-cells represent an advanced cell therapy approach where a patient's T-cells are genetically engineered to express a chimeric antigen receptor (CAR). This CAR is designed with a nanobody as its antigen-binding domain, specifically targeting the CD5 protein, which is commonly found on the surface of malignant T-cells. The smaller size and lower immunogenicity of nanobodies, compared to conventional antibodies, are intended to enhance the safety and efficacy of the therapy. Upon encountering CD5-positive cancer cells, these modified T-cells are activated to recognize and eliminate the cancerous cells. This therapy is currently under investigation for the treatment of T-cell malignancies, including T-cell lymphoma and T-cell acute lymphoblastic leukemia/lymphoma. Hebei Senlangbio Biotechnology Co., Ltd. is involved in the development of a nanobody-based anti-CD5 CAR-T therapy.
- Other names
- Nanobody-Based Anti-CD5 CAR-TCD5 CAR-T cells based on nanobodyCD-5 CAR-T cells based on nanobodyCD 5 CAR-T cells based on nanobody
02
Targets
CD5 (T-cell surface glycoprotein CD5)
Beyond the preview
Go deeper on nanobody CD5-chimeric antigen receptor T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanobody CD5-chimeric antigen receptor T-cells.